Kir3dl2 Mutation May Define a High Rate of Response of Aitl to Tipifarnib

Hematological Oncology - United Kingdom
doi 10.1002/hon.20_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Stochastic Activation of a DNA Damage Response Causes Cell-To-Cell Mutation Rate Variation

Science
MultidisciplinaryPhilosophy of ScienceHistory
2016English

Kir3dl2 Is Expressed in Peripheral T-Cell Lymphomas and May Be a Therapeutic Target

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Evidence for a High Mutation Rate at Rapidly Evolving Yeast Centromeres

BMC Evolutionary Biology
EvolutionEcologySystematicsBehavior
2011English

Pharmacotherapy of Hematologic Malignancies With Tipifarnib

Clinical Medicine. Therapeutics
2009English

Loss of HAX-1 May Contribute to the Neurodegeneration Caused by a Kv3.3 Mutation

Biophysical Journal
Biophysics
2019English

Random Forest Segregation of Drug Responses May Define Regions of Biological Significance

Frontiers in Computational Neuroscience
NeuroscienceCellularMolecular Neuroscience
2016English

Somatic Mutation of DNAH Genes Implicated Higher Chemotherapy Response Rate in Gastric Adenocarcinoma Patients

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

High Th17:Treg Ratio May Predict Complete Response to HDIL-2 in the Setting of Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy